Cancer Therapy

Preclinical data supports utility of INGN 241 combination regimens

Published in Women's Health Weekly, March 18th, 2004

Three abstracts evaluating the role of mda-7/IL-24, the active ingredient in Introgen Therapeutics' (INGN) INGN 241, in models of lung and breast cancer were presented at the Society of University Surgeons 65th annual meeting.

Introgen has completed a phase I/II clinical trial with INGN 241 and the data indicates that the therapy has demonstrated activity as a monotherapy in several cancer indications. Due to the multifunctional activity of mda-7/IL-24, which acts as a tumor suppressor, a potent inhibitor of angiogenesis, and an immunostimulating cytokine, INGN 241 may have broad utility as a monotherapy or as a component of combination regimens in a variety of cancer...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2004-03-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry